Neural modulation of cardiac arrhythmias and sudden cardiac death.

D. Zipes,M. Rubart

DOI: https://doi.org/10.1016/J.HRTHM.2005.09.021

IF: 6.779

Heart Rhythm

Abstract:

What problem does this paper attempt to address?

First national report on patients of mental health clinics.

A. Bahn,V. B. Norman

DOI: https://doi.org/10.2307/4590638

1959-11-01

Abstract:A NATIONWIDE program of statistical J L reporting for outpatient psychiatric clinics was established in July 1954 by the Na,tional Institute of Mental Health in cooperation with the State mental health authorities. The purpose of tllis reporting is to provide a nucleus of uniform data on outpatient psychiatric services to aid in planning programs and facilities on a national, State, and community basis. These data also aid clinics in reviewing their own operations. As a practical first step, reporting is limited to the mental health clinics with outpatient services and a psychiatrist in attendance at regularly scheduled hours who takes the medical responsibility for all clinic patients. The first publications derived from the reporting program were a national directory of clinics (1) and a monograph describing the characteristics and staff of outpatient psychiatric clinics (2) based on data submitted for 1954-55 by more than 95 percent of the clinics in the United States. In this article we are summarizing for the firs,t time national data reported on the characteristics of clinic patients and the services they receive based on information for 1955-56. Several State mental health authorities have issued reports on the data submitted by clinics operating in their jurisdictions (3-7). A national report on the community service activities of outpatient psychiatric clinics will be published later. Although the national statistical program limits requested data on patients to a minimum of basic items of information, collection is difficult. The complex and varied pattern of outpatient psychiatric service causes many problems of definition. To yield uniform data, the definition of a patient, type of service, and diagnostic classifications in particular continue to require review and modification. In many instances it was necessary to install new clinic recordkeeping systems and mechanical tabulating procedures at the State level (8). As a result, by 1956 only 499, or 39 percent, of the 1,294 outpatient psychiatric clinics in the United States were reporting information about their patients. The number of clinics reporting, by type of clinic and by State, is shown in table 1. Data on patients were reported for some but not all clinics in most of the States. Reporting procedures have since been established for the clinics of the Veterans Administration, the clinics in New York State, and additional clinics in other States. Since the clinics that reported in 1956 are not Mrs. Bahn is chief and Miss Norman is a staff analytical statistician, Outpatient Studies Section, Biometrics Branch, National Institute of Mental Health, Public Health Service.
[Results of radiotherapy in the year of the Röntgen centenary]

O Esik

1998-03-08

Abstract:In 1996, the three leading radiation oncology periodicals (Int. J. Radiat. Oncol. Biol. Phys.--USA, Radiother. Oncol.--Europe, and Strahlenther. Onkol.--Germany) published 681 papers. Among the different topics, the clinical subjects accounted for almost half (46%) of the total number of publications, followed by radiation physics/techniques (18%) and radiation biology (17%). The 13% of editorials/review articles reflects a considerable endeavor towards integration; the contribution of papers relating to professional organization amounted to 2%. The fact that 1996 was the centennial year of the discovery of the Röntgen rays explains the reasonable proportion (4%) of historical reviews. Within the special topics, prostatic cancer and breast cancer were the two most frequent issues. Dose escalation was the most important tool applied to improve the results of the radiation therapy of tumors with unfavorable prognostic signs or radioresistance. The increase in the applied dose was made possible by a decrease in the planning target volume (PTV), 3D forward and inverse radiation treatment planning, a combination of tomographic (CT/MRI/US) diagnostic methods (image registration/fusion), optimizing algorithms, computer-controlled delivery of radiation dose and electronic portal imaging with in vivo dosimetry. In contrast, the trends in the radiotherapy of tumors with favorable long-term survival (e.g. Hodgkin's disease and seminoma) include a decreased dose and PTV reduction to diminish the late, radiation-related morbidity. Fractionation has remained the only tool of radiobiology routinely used in the everyday clinical practice. A comparison of the results and achievements in the special fields reveals that radiation physics/techniques clearly outstrip clinical subjects and especially radiation biology, as they allow direct and instant exploitation of the advantages offered by computers. It is highly probable, however, that, subsequent to a wider use of computers in clinical subjects and radiation biology, this situation will change.
The Accomplishments and Legacy of Saul Hertz, MD

Bennett S Greenspan,Michael S Hofman,John Buscombe

DOI: https://doi.org/10.2967/jnumed.124.267524

2024-04-01

Abstract:The early history of the use of radioactive iodine (RAI) is complicated and interesting, and also difficult to discover, especially since several histories have presented inaccurate content. This article is a comprehensive review of the accomplishments of Saul Hertz. Extensive use of primary-source verification has clarified several issues, including the question of whether Hertz alone conceived and asked the pivotal question: "Could iodine be made radioactive artificially?"; on what date RAI was first used to treat hyperthyroidism; and why 2 articles on the first use of RAI for treatment of hyperthyroidism, from 2 different sets of authors from the same department of the same institution, appeared adjacent to each other in the same issue of the Journal of the American Medical Association in 1946. Our review also chronicles several major challenges that Hertz overcame to produce his pivotal work. Hertz was clearly the originator and a visionary of RAI therapy in benign and malignant thyroid disease. We believe he can be considered one of the fathers of nuclear medicine. Hertz's paradigm-changing work was a pivotal medical discovery of the 20th century. The legacy of Hertz continues while the application of RAI therapy continues to evolve. RAI therapy remains the preferred treatment in most situations for autonomous nodules and toxic multinodular goiter and remains a safe and effective treatment for Graves disease after more than 80 y of global clinical use. RAI treatment of differentiated thyroid cancer remains a first-line treatment for most patients after surgery, especially for those with intermediate- or high-risk disease.
A Review of the History of Radioactive Iodine Theranostics: The Origin of Nuclear Ontology

John Dennis Ehrhardt Jr,Seza Güleç

DOI: https://doi.org/10.4274/mirt.galenos.2020.83703

2020-10-19

Abstract:Studies on the first years of radioactive iodine (RAI) use in thyroid diseases have focused on hyperthyroidism. Saul Hertz's success with RAI in thyrotoxicosis fueled a seamless transition to Samuel Seidlin's investigations with RAI in thyroid cancer. These landmark events embody nuclear ontology, a philosophical foundation for the creation and existence of radio-therapeutic principles that continue to influence clinical practices today. Laying this ontological foundation, Dr. Saul Hertz who is the founding director of Massachusetts General Hospital Thyroid Clinic, affiliated with Harvard University created a framework for RAI theranostics with preclinical experiments and clinical cases from 1937 to 1942. The first thyroid cancer treatment with RAI was applied in 1942 by Samuel Seidlin. The sensational effect of the first application was interestingly powerful enough to overshadow scientific data. Seidlin and colleagues assembled a sixteen-patient series showcasing a unique entity: functional thyroid metastases that respond to RAI. Other investigations at the time demonstrated that RAI had little efficacy as a therapeutic agent, mainly because most thyroid tumors do not form colloid, and therefore cannot concentrate RAI. These findings were soon overshadowed by a mainstream article in the October 1949 issue of Life that portrayed RAI as a lifesaving therapy for thyroid cancer. The paradigm was set, and later writings by William H. Beierwaltes and other prominent nuclear medicine physicians established the primary goals and principles of RAI therapy. The developments in theoretical physics and nuclear instrumentation and the scientists who made these developments in the early years contributed greatly to the development of the concept. In the field of nuclear medicine, William H. Beierwaltes has gone down in our history as a clinical researcher with his most important contributions. The classical paradigm that started with him has carried us to today's molecular theranoistic viewpoint. This paper examines controversial topics in the advent of thyroid theranostics, and applies historical significance to current discussions on the role of RAI in thyroid cancer management. Another paradigm shift is on the horizon as thyroidology enters the age of genomics. The molecular theranostic profiles will soon be incorporated into a dynamic clinical decision-making and management algorithm for thyroid surgery and RAI therapy. From now on, nuclear oncology will gain a new ontological identity with molecular pathology and new theranostic expansions.
Pfitzner and Musical Politics

L. Botstein

DOI: https://doi.org/10.1093/MUSQTL/85.1.63

2001-03-20

Abstract:It should come as no surprise that the repertory of concert houses and opera stages is slowly expanding to include works that were successful and highly regarded in the past but have since all but vanished from the stage. Canonical status in the active repertory derives from a murky process that can hardly be described as an objective verdict of history in terms of normative aesthetic value. On e of the constants in that process is the pressure exerted by the character and flow of new contemporary works. The new helps push out the old. Which parts of the once new disappear is determined in turn by the nature of what seems novel and succeeds.with audiences and critics in new music and the way history is, as a consequence, steadily rewritten. Wha t is relatively anomalous is the fact that since the early twentieth century we have found ourselves faced with an ever-weakening pressure from the new. Despite some optimistic signs, including a growing number of new operas and a cadre of successful young composers, the demand for contemporary music still remains weaker than it was a century ago and than it should be. Since constant repetition in live performance, even of Mahler's symphonies or Puccini's La Boheme, is in the end implausible, the inevitable demand for something new is now being filled by a reconsideration of what the past has still to offer. Historical revisionism occupies a place once reserved for contemporary repertory, particularly in North America. This is not altogether bad, since there are treasures of first-class material languishing in the proverbial archives of the nineteenth and twentieth centuries. The only question is which ones we choose to revive and in what sequence of priority. Valery Gergiev has pioneered the rediscovery of the neglected Russian opera repertory. His is clearly a nationalistic enterprise, based at the Kirov, whose efforts he deftly exports. Sir Charles Mackerras has helped bring Janacek beyond ]en&fa to the fore, but in terms of the Czech repertory, our familiarity with the dramatic works of Dvorak and Smetana in performance still lags. There is much to look forward to.
Overview of the History of Turkish Radiology in the Light of Archives Documents (1896-1933)

Fuat İNCE,Kadircan KESKİNBORA

DOI: https://doi.org/10.31020/mutftd.1238285

2023-05-04

Mersin Üniversitesi Tıp Fakültesi Lokman Hekim Tıp Tarihi ve Folklorik Tıp Dergisi

Abstract:Purpose: To describe the birth of radiology and, its development in the late Ottoman period and during the Republic's early years in Turkiye, and to share information obtained by examining official archive documents. Method: The study was designed as a document analysis in qualitative research. Publications about the subject were examined, Turkish State Archives were scanned, and documents were analyzed. Results: With the discovery of the X-Ray by the German scientist Röntgen, a new leaf was turned over in the history of world medicine. Turkiye has introduced X-rays in 1896, thanks to Esad Feyzi. In the 1897 Ottoman-Greek War, X-Rays were used to aid surgery. The first experiment with X-Ray treatment in Turkiye was made in 1899 by Cemil Pasha. In 1902, a radiotherapy unit was established in Istanbul. After the Republic X-Ray machines were purchased for newly established hospitals, and radiology laboratories were established in the country. Developments in the Ottoman period continued. Conclusion: To be able to continue successfully Turkiye's radiology adventure beginning in 1896, it is very important to emphasize education as it is before and maybe more, to train qualified manpower, to employ them in the right places, to follow the developments in the world, and to have centers with modern equipment.
Radioligand Therapy in Lymphoma: Past, Present, and Future

Ludmila Santiago Almeida,Roberto C Delgado Bolton,Victor Cabral Heringer,Samuel de Souza Medina,Elba Etchebehere

DOI: https://doi.org/10.1016/j.cpet.2024.05.003

Abstract:In the1980s, radiolabeled cells helped understand the pathology of hemato-oncology. In the 1990s, preclinical trials evaluated radiolabeled immunotherapy with monoclonal antibodies (MoAbs) such as anti-CD20 agents labeled with Iodine-131 (Bexxar) or Yttrium-90 (Zevalin). Due to the safe and durable responses of radiolabeled MoAbs, the Food and Drug Administration approved these agents in the 2000s. Despite radioimmunotherapy's long journey, its application has recently decreased. This review will discuss the historical timeline of radioimmunotherapy, debate on advantages and difficulties, and explore trials. We will examine future directions of radioligand therapy in hemato-oncology, considering emerging molecules that may become the next theragnostic trend.
Effects of two adhesion boosters on the shear bond strength of new and rebonded orthodontic brackets.

C. Chung,B. Fadem,H. L. Levitt,F. Mante

DOI: https://doi.org/10.1067/MOD.2000.104810

IF: 2.711

2000-09-01

American Journal of Orthodontics and Dentofacial Orthopedics

Abstract:The purpose of this study was to evaluate the effects of 2 adhesion boosters, Enhance LC (Reliance, Itasca, Ill) and All-Bond 2 (Bisco, Schaumburg, Ill), on the shear bond strength of new and rebonded (previously debonded) brackets. Sixty new and 60 sandblasted rebonded brackets were bonded to 120 extracted human premolars with composite resin and divided equally into 6 groups based on the 2 adhesion boosters used: (1) new brackets/no booster (2) rebonded brackets/no booster (3) new brackets/Enhance (4) rebonded brackets/Enhance (5) new brackets/All-Bond (6) rebonded brackets/All-Bond. Shear bond strength of each sample was tested with an Instron machine (Instron Corp, Canton, Mass). Results show that the new brackets/All-Bond group yielded the highest strength (20.8 +/- 7.5 MPa), followed by the new brackets/Enhance group (18.6 +/- 6.5 MPa), rebond brackets/All-Bond group (17.3 +/- 7.2 MPa), new brackets/no booster group (16.8 +/- 6.3 MPa), rebonded brackets/no booster group (14.2 +/- 7.2 MPa), and rebonded brackets/Enhance group (13.6 +/- 6.7 MPa). No statistically significant difference was found among the 3 groups utilizing new brackets. For groups of rebonded brackets/no booster and rebonded brackets/Enhance, bond strength was significantly lower than groups of 3 new brackets and rebonded brackets/All-Bond. Rebonded brackets/All-Bond group had comparable bond strength to all 3 new brackets groups. It was concluded that in the process of replacing a failed bracket, (1) when new brackets are used, neither All-Bond 2 or Enhance LC improves bond strength significantly, (2) without the use of any adhesion booster, sandblasted rebonded brackets yield significantly less bond strength than new brackets, (3) Enhance LC fails to increase bond strength of sandblasted rebonded brackets, (4) All-Bond 2 significantly increases bond strength of sandblasted rebonded brackets, (5) sandblasted rebonded brackets with All-Bond 2 yield comparable bond strength to new brackets.
Imaging in France: 2024 Update

Maxime Barat,Amandine Crombé,Tom Boeken,Jean-Nicolas Dacher,Salim Si-Mohamed,Anthony Dohan,Guillaume Chassagnon,Augustin Lecler,Joel Greffier,Stéphanie Nougaret,Philippe Soyer

DOI: https://doi.org/10.1177/08465371241288425

2024-10-07

Canadian Association of Radiologists Journal

Abstract:Canadian Association of Radiologists Journal, Ahead of Print. Radiology in France has made major advances in recent years through innovations in research and clinical practice. French institutions have developed innovative imaging techniques and artificial intelligence applications in the field of diagnostic imaging and interventional radiology. These include, but are not limited to, a more precise diagnosis of cancer and other diseases, research in dual-energy and photon-counting computed tomography, new applications of artificial intelligence, and advanced treatments in the field of interventional radiology. This article aims to explore the major research initiatives and technological advances that are shaping the landscape of radiology in France. By highlighting key contributions in diagnostic imaging, artificial intelligence, and interventional radiology, we provide a comprehensive overview of how these innovations are improving patient outcomes, enhancing diagnostic accuracy, and expanding the possibilities for minimally invasive therapies. As the field continues to evolve, France's position at the forefront of radiological research ensures that these innovations will play a central role in addressing current healthcare challenges and improving patient care on a global scale.

radiology, nuclear medicine & medical imaging
Tracing the Evolution of Prostate Brachytherapy in the 20th Century

Michael S Schaulin,Guila Delouya,Daniel Zwahlen,Daniel Taussky

DOI: https://doi.org/10.1159/000534017

Oncology

Abstract:Background: Prostate brachytherapy (BT) techniques have evolved over the past century. This paper aimed to preserve our collective memory of history and the early development of its technique. We searched articles in PubMed and Google Scholar using keywords referring to authors, dates, and BT technical details, including different radioactive sources and country-specific publications. We reviewed the work published by Holm and Aronowitz. The digital library Internet Archives was used to retrieve original journal articles, science newspaper printings, and government reports, which allowed us to situate the development of BT in its sociopolitical context in Europe and the USA. Our search was conducted in English, French, and German languages. Summary: Early BT methods were developed by European physicians with early access to radium. Technical advancements were made by HH Young, who brought this practice to the USA, where Barringer pioneered the use of radon seeds and low-dose interstitial brachytherapy. While centralized radiotherapy centers, such as Memorial Hospital in New York, emerged for training and research, the high cost of radium and opposing interests made brachytherapy harder to implement in Germany. After World War II, the introduction of man-made radioisotopes allowed experiments with colloidal solutions and new seeds, including I-125. In the 1980s, transrectal ultrasound allowed for more accurate radioactive seed insertion and replaced the transrectal finger guidance.
Cancer and Radiation Therapy: Current Advances and Future Directions

Rajamanickam Baskar,Kuo Ann Lee,Richard Yeo,Kheng-Wei Yeoh

DOI: https://doi.org/10.7150/ijms.3635

2012-01-01

International Journal of Medical Sciences

Abstract:In recent years remarkable progress has been made towards the understanding of proposed hallmarks of cancer development and treatment. However with its increasing incidence, the clinical management of cancer continues to be a challenge for the 21st century. Treatment modalities comprise of radiation therapy, surgery, chemotherapy, immunotherapy and hormonal therapy. Radiation therapy remains an important component of cancer treatment with approximately 50% of all cancer patients receiving radiation therapy during their course of illness; it contributes towards 40% of curative treatment for cancer. The main goal of radiation therapy is to deprive cancer cells of their multiplication (cell division) potential. Celebrating a century of advances since Marie Curie won her second Nobel Prize for her research into radium, 2011 has been designated the Year of Radiation therapy in the UK. Over the last 100 years, ongoing advances in the techniques of radiation treatment and progress made in understanding the biology of cancer cell responses to radiation will endeavor to increase the survival and reduce treatment side effects for cancer patients. In this review, principles, application and advances in radiation therapy with their biological end points are discussed.

medicine, general & internal
Interaction of selective compounds with muscarinic receptors at dispersed intestinal smooth muscle cells

E. Barocelli,M. Chiavarini,V. Ballabeni,F. Bordi,M. Impicciatore

DOI: https://doi.org/10.1111/j.1476-5381.1993.tb12815.x

IF: 7.3

1993-02-01

British Journal of Pharmacology

Abstract:1 The characterization of muscarinic receptors on single cells of the guinea‐pig ileum longitudinal smooth muscle, devoid of neuronal elements, was functionally studied by estimating the affinities of muscarinic antagonists on acetylcholine‐induced contractions. 2 Atropine (5 × 10−11 to 5 × 10−6 m), 4‐diphenylacetoxy‐N‐methyl‐piperidine methiodide (4‐DAMP, 5 × 10−8 to 5 × 10−6 m), cyclohexyl(4‐fluoro‐phenyl) (3‐piperidinopropyl) silanol (pFHHSiD, 5 × 10−7 to 5 × 10−5 m) as well as pirenzepine (5 × 10−7 to 5 × 10−5 m) competitively antagonized the acetylcholine‐dependent contractions with different affinities (atropine > 4‐DAMP > pFHHSiD > pirenzepine). 3 Methoctramine (5 × 10−7 to 5 × 10−5 m), and AF‐DX 116 (5 × 10−6 and 5 × 10−5 m) also showed antagonist properties but these deviated from simple competition. These compounds, which discriminate between M2 and M3 receptors, showed a potency lower than that of pirenzepine, the rank order of potencies being pirenzepine > methoctramine > AF‐DX 116. When concentrations of AF‐DX 116, methoctramine and pirenzepine were increased an unspecific contractile effect occurred. 4 McN‐A‐343, a partial agonist on intact guinea‐pig longitudinal smooth muscle strips, on this preparation induced a weak contraction (about 7% in comparison to control) that was not reversed by antimuscarinic agents. 5 These data indicate that M3 rather than M2 receptor sites are present on this tissue.
The visual diplomacy of cancer treatments: the mediatic legacy of the Curies in the early transnational fight against cancer

Beatriz Medori

DOI: https://doi.org/10.1017/S0007087423000109

Abstract:This paper analyses the role played by members of the Curie family in the visual diplomacy of cancer treatments. This relationship started in 1921, when Marie Curie travelled to the US, accompanied by her two daughters, Ève and Irène, to receive a gram of radium at the White House from President Warren Harding. In the years that followed, Ève Curie, as the biographer and natural heir of radium discoverers Marie and Pierre Curie, continued to contribute to the visual diplomacy of cancer campaigning. Two events will be analysed through an interdisciplinary lens, merging history of science and visual-diplomacy studies, to show how the legacy of the Curies played out in the international consolidation of pre-war transnational alliances in the fight against cancer. One involves the picture of the chargé d'affaires of the France Republic, Jules Henry, receiving the biography authored by Ève, Madame Curie, at the French embassy in Washington. The other concerns the photograph of Ève visiting the Portuguese Oncology Institute (IPO) in 1940, which was immediately reproduced in the Institute's bulletin in order to raise awareness of cancer prevention strategies, and also captured in film as a propaganda tool for the Estado Novo regime (1933-74).
Prevention and treatment of acute and chronic radiodermatitis

Sophie Seité,René-Jean Bensadoun,Jean-Michel Mazer

DOI: https://doi.org/10.2147/bctt.s149752

2017-11-01

Breast Cancer: Targets and Therapy

Abstract:More than half the number of patients with cancer, who are treated with radiotherapy, will have radiodermatitis at some point during their treatment. Radiodermatitis either occurs early on in the treatment period or appears months or up to several years later. Acute radiodermatitis is a burn injury that varies in severity according to both treatment and inherent patient factors. Most acute radiodermatitis reactions resolve after several weeks but some reactions persist and can cause complications. Late-onset radiodermatitis is characterized by telangiectasia that forms on atrophic and fragile skin. These radiodermatitis reactions can have a significant negative impact on concomitant and subsequent therapeutic protocols and most particularly on the patient's quality of life. Today, treatment of radiodermatitis reactions is in its infancy. Although there is insufficient evidence available to form recommendations that would prevent or reduce radiodermatitis, some advances have been made using low level light therapy (LLLT) or vascular lasers to control the symptoms. Some recent preclinical and clinical research suggests that LLLT has biostimulating properties which allow the tissues to regenerate and heal faster, reduce inflammation, and prevent fibrosis. Also, in late-onset radiodermatitis pulsed dye laser treatment has been shown to be beneficial in clearing radiation-induced telangiectasia. In the absence of evidence-based recommendations, the objective of this paper is to review how to prevent or manage the symptoms of radiodermatitis reactions.
Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

Nicolas Lepareur,Franck Lacœuille,Christelle Bouvry,François Hindré,Emmanuel Garcion,Michel Chérel,Nicolas Noiret,Etienne Garin,F. F. Russ Knapp

DOI: https://doi.org/10.3389/fmed.2019.00132

IF: 3.9

2019-06-14

Frontiers in Medicine

Abstract:Rhenium-188 (188Re) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-life, which has been shown to be a very attractive candidate for use in therapeutic nuclear medicine. The high beta emission has an average energy of 784 keV and a maximum energy of 2.12 MeV, sufficient to penetrate and destroy targeted abnormal tissues. In addition, the low-abundant gamma emission of 155 keV (15%) is efficient for imaging and for dosimetric calculations. These key characteristics identify 188Re as an important therapeutic radioisotope for routine clinical use. Moreover, the highly reproducible on-demand availability of 188Re from the 188W/188Re generator system is an important feature and permits installation in hospital-based or central radiopharmacies for cost-effective availability of no-carrier-added (NCA) 188Re. Rhenium-188 and technetium-99 m exhibit similar chemical properties and represent a "theranostic pair." Thus, preparation and targeting of 188Re agents for therapy is similar to imaging agents prepared with 99mTc, the most commonly used diagnostic radionuclide. Over the last three decades, radiopharmaceuticals based on 188Re-labeled small molecules, including peptides, antibodies, Lipiodol and particulates have been reported. The successful application of these 188Re-labeled therapeutic radiopharmaceuticals has been reported in multiple early phase clinical trials for the management of various primary tumors, bone metastasis, rheumatoid arthritis, and endocoronary interventions. This article reviews the use of 188Re-radiopharmaceuticals which have been investigated in patients for cancer treatment, demonstrating that 188Re represents a cost effective alternative for routine clinical use in comparison to more expensive and/or less readily available therapeutic radioisotopes.

medicine, general & internal
The risk of cancer attributable to diagnostic medical radiation: Estimation for France in 2015

Claire Marant-Micallef,Kevin D Shield,Jérôme Vignat,Enora Cléro,Ausrele Kesminiene,Catherine Hill,Agnès Rogel,Blandine Vacquier,Freddie Bray,Dominique Laurier,Isabelle Soerjomataram

DOI: https://doi.org/10.1002/ijc.32048

2019-06-15

Abstract:Although medical ionizing radiation (IR) has clear clinical benefits, it is an established carcinogen. Our study estimates the number of new cancer cases in France in 2015 attributable to IR exposure from medical procedures. Exposures from external (X-rays, CT scans, interventional radiology) and internal (nuclear medicine) sources were considered. We used 2007 national frequencies of diagnostic examinations by sex and age to estimate the lifetime organ dose exposure adjusted for changes in the use of such procedures over time. The Biological Effects of Ionizing Radiation VII risk models were used to estimate the corresponding excess cancer risk, assuming an average latency period of 10 years. Additionally, we used cancer incidence data from the French Cancer Registries Network. Of the 346,000 estimated new cancer cases in adults in France in 2015, 2300 cases (940 among men and 1360 among women) were attributable to diagnostic IR, representing 0.7% of all new cancer cases (0.5% for men and 0.9% for women). The leading cancers attributable to medical IR were female breast (n = 560 cases), lung (n = 500 cases) and colon (n = 290 cases) cancers. Compared to other risk factors, the contribution of medical IR to the cancer burden is small, and the benefits largely outweigh its harms. However, some of these IR-associated cancer cases may be preventable through dose optimization of and enhanced justification for diagnostic examinations.
New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

Claudia Burkhardt,Léo Bühler,David Viertl,Thierry Stora

DOI: https://doi.org/10.3389/fmed.2021.674656

IF: 3.9

2021-08-02

Frontiers in Medicine

Abstract:The use of radioactivity in medicine has been developed over a century. The discovery of radioisotopes and their interactions with living cells and tissue has led to the emergence of new diagnostic and therapeutic modalities. The CERN-MEDICIS infrastructure, recently inaugurated at the European Center for Nuclear Research (CERN), provides a wide range of radioisotopes of interest for diagnosis and treatment in oncology. Our objective is to draw attention to the progress made in nuclear medicine in collaboration with CERN and potential future applications, in particular for the treatment of aggressive tumors such as pancreatic adenocarcinoma, through an extensive review of literature. Fifty seven out of two hundred and ten articles, published between 1997 and 2020, were selected based on relevancy. Meetings were held with a multi-disciplinary team, including specialists in physics, biological engineering, chemistry, oncology and surgery, all actively involved in the CERN-MEDICIS project. In summary, new diagnostic, and therapeutic modalities are emerging for the treatment of pancreatic adenocarcinoma. Targeted radiotherapy or brachytherapy could be combined with existing therapies to improve the quality of life and survival of these patients. Many studies are still in the pre-clinical stage but open new paths for patients with poor prognosis.

medicine, general & internal
Laws That Have Shaped Radiology: Part I

Gyan Moorthy,Leah Bush,Anne Zimmerman,Saurabh Jha

DOI: https://doi.org/10.1016/j.acra.2024.08.054

2024-09-17

Abstract:Radiology began as a translation of quantum physics to clinical medicine. Advances in computing and engineering enabled the differentiation of the field into diagnostic radiology, interventional radiology, and radiation oncology as practical responses to rapidly proliferating medical knowledge. Radiology has itself transformed modern medicine, helping clinicians identify, track, and intervene on multiple once deadly diseases. It is practiced in academic departments and hospital based, outpatient center based, or fully remote private groups of varying sizes, often with direct physicist support to optimize the use of complicated equipment. Importantly, radiology was guided to its current form not just by scientific advances, but by the interplay of cultural and governmental forces, as well as hard lessons, the results of constantly shifting balances of competing interests as follows: insurance, pharmaceutical, medical device, hospital, physician, physician extender, and patient. The purpose of this review is to describe the historical legal landscape of diagnostic radiology in the context of ethics, public health initiatives, and patient protections. For clarity, the review is divided into two parts.
Radiotherapy for non-cancer diseases: benefits and long-term risks

Juliette Thariat,Mark P. Little,Lydia B. Zablotska,Pamela Samson,M. Kerry O'Banion,Klervi Leuraud,Carmen Bergom,Gilles Girault,Omid Azimzadeh,Simon Bouffler,Nobuyuki Hamada

DOI: https://doi.org/10.1080/09553002.2023.2295966

2024-01-06

International Journal of Radiation Biology

Abstract:Purpose The discovery of X-rays was followed by a variety of attempts to treat infectious diseases and various other non-cancer diseases with ionizing radiation, in addition to cancer. There has been a recent resurgence of interest in the use of such radiotherapy for non-cancer diseases. Non-cancer diseases for which use of radiotherapy has currently been proposed include refractory ventricular tachycardia, neurodegenerative diseases (e.g. Alzheimer's disease and dementia), and Coronavirus Disease 2019 (COVID-19) pneumonia, all with ongoing clinical studies that deliver radiation doses of 0.5–25 Gy in a single fraction or in multiple daily fractions. In addition to such non-cancer effects, historical indications predominantly used in some countries (e.g. Germany) include osteoarthritis and degenerative diseases of the bones and joints. This narrative review gives an overview of the biological rationale and ongoing preclinical and clinical studies for radiotherapy proposed for various non-cancer diseases, discusses the plausibility of the proposed biological rationale, and considers the long-term radiation risks of cancer and non-cancer diseases.

radiology, nuclear medicine & medical imaging,biology,nuclear science & technology
Professor Anastas Kocarev, First Macedonian Oncologist with Worldwide Reputation and Pioneer in Cancer Diagnostics and Treatment with Radium

Doncho Donev,Ljupcho Kocarev,Momir Polenakovic

DOI: https://doi.org/10.2478/prilozi-2020-0012

2019-12-01

Abstract:PhD. Anastas Kocarev (Kotzareff in French) is one of the most prominent Macedonian doctors and experts, prolific contributor to the cancer research in Switzerland and France in the first decades of the 20th century. He was born in Ohrid on May 5th, 1889. He graduated from the Faculty of Medicine in Geneva where he defended a doctorate in medicine in 1915. In 1916 he was elected Assistant Professor (Private Docent) at that Faculty. He was a prominent scientist and professor of experimental medicine at the Faculty of Medicine in Geneva and the Sorbonne University in Paris, with a wide reputation in Europe and the United States. PhD. A. Kocarev is one of the pioneers of oncology and radiology in the world, a forerunner of modern nuclear medicine and positron emission tomography. He was a close associate of Nobel laureate in chemistry and physics Maria Sklodovska-Curie and at her invitation moved to Paris in 1925 to continue the research on the diagnosis and treatment of cancer using radium. He was fully devoted to science and published numerous scientific papers and books with high citations and dissemination in many medical libraries in Europe and beyond. In addition to his professional teaching and scientific work as a top oncologist-radiologist, he was a great patriot with advanced political ideas. He founded the Academic Society "Macedonia" in Geneva, in 1915, and united it with other Macedonian political associations from Zurich and Lausanne, in 1918, into a joint "Alliance of Macedonian Societies for Independent Macedonia", with commitments, activities and initiatives to the Society of Nations, based in Geneva, Switzerland, for the proper resolution of the Macedonian national issue by creating a united and independent state "Macedonia" or the formation of a "Balkan Federation". He died suddenly in Paris on March 29, 1931.

Neural modulation of cardiac arrhythmias and sudden cardiac death.

First national report on patients of mental health clinics.

[Results of radiotherapy in the year of the Röntgen centenary]

The Accomplishments and Legacy of Saul Hertz, MD

A Review of the History of Radioactive Iodine Theranostics: The Origin of Nuclear Ontology

Pfitzner and Musical Politics

Overview of the History of Turkish Radiology in the Light of Archives Documents (1896-1933)

Radioligand Therapy in Lymphoma: Past, Present, and Future

Effects of two adhesion boosters on the shear bond strength of new and rebonded orthodontic brackets.

Imaging in France: 2024 Update

Tracing the Evolution of Prostate Brachytherapy in the 20th Century

Cancer and Radiation Therapy: Current Advances and Future Directions

Interaction of selective compounds with muscarinic receptors at dispersed intestinal smooth muscle cells

The visual diplomacy of cancer treatments: the mediatic legacy of the Curies in the early transnational fight against cancer

Prevention and treatment of acute and chronic radiodermatitis

Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives

The risk of cancer attributable to diagnostic medical radiation: Estimation for France in 2015

New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini Review

Laws That Have Shaped Radiology: Part I

Radiotherapy for non-cancer diseases: benefits and long-term risks

Professor Anastas Kocarev, First Macedonian Oncologist with Worldwide Reputation and Pioneer in Cancer Diagnostics and Treatment with Radium